These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 22105711)
1. Effects of point mutations in pVHL on the binding of HIF-1α. Domene C; Illingworth CJ Proteins; 2012 Mar; 80(3):733-46. PubMed ID: 22105711 [TBL] [Abstract][Full Text] [Related]
2. Simulation of the mutation F76del on the von Hippel-Lindau tumor suppressor protein: mechanism of the disease and implications for drug development. Limaverde-Sousa G; Barreto Ede A; Ferreira CG; Casali-da-Rocha JC Proteins; 2013 Feb; 81(2):349-63. PubMed ID: 23011899 [TBL] [Abstract][Full Text] [Related]
3. Proline hydroxylation at different sites in hypoxia-inducible factor 1α modulates its interactions with the von Hippel-Lindau tumor suppressor protein. Qian H; Zou Y; Tang Y; Gong Y; Qian Z; Wei G; Zhang Q Phys Chem Chem Phys; 2018 Jul; 20(27):18756-18765. PubMed ID: 29961792 [TBL] [Abstract][Full Text] [Related]
4. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL. Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690 [TBL] [Abstract][Full Text] [Related]
5. STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination. Jung JE; Kim HS; Lee CS; Shin YJ; Kim YN; Kang GH; Kim TY; Juhnn YS; Kim SJ; Park JW; Ye SK; Chung MH Exp Mol Med; 2008 Oct; 40(5):479-85. PubMed ID: 18985005 [TBL] [Abstract][Full Text] [Related]
6. Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design. Liu J; Nussinov R Proc Natl Acad Sci U S A; 2008 Jan; 105(3):901-6. PubMed ID: 18195360 [TBL] [Abstract][Full Text] [Related]
7. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex. Miller F; Kentsis A; Osman R; Pan ZQ J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064 [TBL] [Abstract][Full Text] [Related]
8. Chemical basis for the selectivity of the von Hippel Lindau tumor suppressor pVHL for prolyl-hydroxylated HIF-1alpha. Illingworth CJ; Loenarz C; Schofield CJ; Domene C Biochemistry; 2010 Aug; 49(32):6936-44. PubMed ID: 20695530 [TBL] [Abstract][Full Text] [Related]
9. Homology modeling and molecular dynamics simulation of the HIF2α degradation-related HIF2α-VHL complex. Dong X; Su X; Yu J; Liu J; Shi X; Pan Q; Yang J; Chen J; Li L; Cao H J Mol Graph Model; 2017 Jan; 71():116-123. PubMed ID: 27902963 [TBL] [Abstract][Full Text] [Related]
10. USP9X destabilizes pVHL and promotes cell proliferation. Zhang C; Peng Z; Zhu M; Wang P; Du X; Li X; Liu Y; Jin Y; McNutt MA; Yin Y Oncotarget; 2016 Sep; 7(37):60519-60534. PubMed ID: 27517496 [TBL] [Abstract][Full Text] [Related]
11. Role of Ran-regulated nuclear-cytoplasmic trafficking of pVHL in the regulation of microtubular stability-mediated HIF-1α in hypoxic cardiomyocytes. Jiang X; Zhang D; Zhang H; Huang Y; Teng M Sci Rep; 2015 Mar; 5():9193. PubMed ID: 25779090 [TBL] [Abstract][Full Text] [Related]
12. In silico investigation of PHD-3 specific HIF1-α proline 567 hydroxylation: a new player in the VHL/HIF-1α interaction pathway? Minervini G; Masiero A; Moro S; Tosatto SC FEBS Lett; 2013 Sep; 587(18):2996-3001. PubMed ID: 23886708 [TBL] [Abstract][Full Text] [Related]
13. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293 [TBL] [Abstract][Full Text] [Related]
15. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis. Forman JR; Worth CL; Bickerton GR; Eisen TG; Blundell TL Proteins; 2009 Oct; 77(1):84-96. PubMed ID: 19408298 [TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions. Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849 [TBL] [Abstract][Full Text] [Related]
17. Quantifying the Binding Interaction between the Hypoxia-Inducible Transcription Factor and the von Hippel-Lindau Suppressor. Domene C; Jorgensen C; Vanommeslaeghe K; Schofield CJ; MacKerell A J Chem Theory Comput; 2015 Aug; 11(8):3946-54. PubMed ID: 26574473 [TBL] [Abstract][Full Text] [Related]
18. Immunoexpression patterns for Hypoxia-inducible Factor-1α and von Hippel-Lindau protein, in relation to Hsp90, of human brain tumors. Assimakopoulou M; Androutsopoulou C; Zolota V; Matsoukas J Histol Histopathol; 2016 May; 31(5):535-46. PubMed ID: 26592496 [TBL] [Abstract][Full Text] [Related]
19. Runx2 protein stabilizes hypoxia-inducible factor-1α through competition with von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes. Lee SH; Che X; Jeong JH; Choi JY; Lee YJ; Lee YH; Bae SC; Lee YM J Biol Chem; 2012 Apr; 287(18):14760-71. PubMed ID: 22351759 [TBL] [Abstract][Full Text] [Related]
20. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]